MedPath

Laser at Lumbar Acupoint on Pain and Quality of Life in Chronic Pelvic Pain

Not Applicable
Completed
Conditions
Pelvic Pain
Interventions
Device: low level laser therapy
Other: non-steroidal drugs
Registration Number
NCT05537207
Lead Sponsor
October 6 University
Brief Summary

To investigate the effect of low-level laser at lumbar sensitized acupoint on pain perception in chronic pelvic pain. BACKGROUND: chronic pelvic pain is one of the serious problems in the female, resulting in pain and less physical activity.

Detailed Description

Thirty six females with chronic pelvic pain will participate in this study. The patients will randomly be divided into two equal groups; the control group will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will described by their gynecologist. and the study group received the same treatment and low-level laser at lumbar sensitized Acupoint, three times per week for four weeks. The evaluation methods by visual analogue scale (VAS), pain sensitivity was evaluated by measuring mean values of pressure pain thresholds (PPT) using a Pressure Algometer, while the quality of life was evaluated by the 12-Item Short-Form Health Survey (SF-12) before and after the treatment

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
36
Inclusion Criteria
  • Thirty six female with chronic pelvic pain

    • Their age ranged from 25 to 40 years old.
    • With the maximum parity number three.
    • Their body mass index (BMI) (20:29.9) kg/m2.
    • their pain score on the Visual Analog Scale (VAS) above 4 cm
    • Thirty-six married women diagnosed with chronic pelvic pain (CPP)
    • with a prior history of treatment for pelvic inflammatory disease (PID)
    • women with periodic lower abdominal or pelvic pain for at least six months and met -- the clinical diagnostic criteria for PID based on the presence of all three major criteria: lower abdominal tenderness, cervical motion tenderness, and bilateral adnexal tenderness
    • at least one minor supporting criterion: oral temperature >38.3°C (101 °F), mucopurulent cervical discharge or cervical friability, abundant WBCs on saline microscopy of vaginal fluid, elevated ESR and/or CRP, or laboratory-confirmed cervical infection with N.

gonorrhoeae or C. trachomatis

Exclusion Criteria
  • Any difficulty to communicate or understanding program instructions
  • any other conditions that caused pain (for example fibromyalgia and arthritis)
  • any psychiatric or cognitive symptoms
  • any other musculoskeletal disorders or neurologic diseases
  • any other conditions causing pelvic pain (e.g., fibromyalgia, arthritis), history of musculoskeletal or neurological diseases affecting the lower extremities and spine (such as lumbar disc herniation), acute pelvic inflammatory disease (PID), pregnancy or lactation, tumors, pelvic congestion, tuberculous PID, endometriosis, adenomyosis, gynecological tumors, or other gyneco-logical conditions that could contribute to chronic pelvic pain (CPP).
  • any issues at acupoint sites (such as ulcers or skin conditions); impairments in other systems that could lead to pelvic and lumbosacral pain (e.g., digestive, motor, or urinary issues)
  • severe systemic illnesses affecting the hematologic, digestive, urinary, or cardiovascular systems
  • mental illness; cognitive deterioration
  • immune-compromising diseases (such as diabetes or HIV/AIDS); and contraindications to NSAIDs

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
study grouplow level laser therapylow level laser therapy (LLLT) on the acupuncture points.in addition to non-steroidal anti-inflammatory drugs
study groupnon-steroidal drugslow level laser therapy (LLLT) on the acupuncture points.in addition to non-steroidal anti-inflammatory drugs
control groupnon-steroidal drugsAll women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as will be described by their gynecologist.
Primary Outcome Measures
NameTimeMethod
visual analogue scale4 weeks

which assesses pain on a paper sheet scale with an increasing number from 0 (no pain) to 10 (the worst pain imaginable).

Pressure Algometer4 weeks

pain sensitivity was evaluated by measuring mean values of pressure pain thresholds (PPT) using a Pressure Algometer. it will be used to assess pain sensitivity through identifying the pressure pain threshold (PPT) for all women before and after treatment. It has a standardized 1.52 cm2 flat circular probe that is pushed against the subject until the pain threshold is reached

Short-Form Health Survey4 weeks

quality of life was evaluated by the 12-Item Short-Form Health Survey (SF-12) before and after the treatment. it is a 12-item questionnaire that was used to assess the quality of life of women in both groups

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Lama S Mahmoud

🇪🇬

Al Jīzah, Select State, Egypt

© Copyright 2025. All Rights Reserved by MedPath